245 related articles for article (PubMed ID: 26245851)
21. Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
Yamaguchi T; Iwasa S; Nagashima K; Ikezawa N; Hamaguchi T; Shoji H; Honma Y; Takashima A; Okita N; Kato K; Yamada Y; Shimada Y
Anticancer Res; 2016 Jul; 36(7):3531-6. PubMed ID: 27354619
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
Lv ZC; Ning JY; Chen HB
Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
[TBL] [Abstract][Full Text] [Related]
23. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
Bando H; Yoshino T; Yuki S; Shinozaki E; Nishina T; Kadowaki S; Yamazaki K; Kajiura S; Tsuchihara K; Fujii S; Yamanaka T; Ohtsu A
Jpn J Clin Oncol; 2012 Dec; 42(12):1146-51. PubMed ID: 23071293
[TBL] [Abstract][Full Text] [Related]
25. A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.
Sato Y; Hirakawa M; Ohnuma H; Takahashi M; Okamoto T; Okamoto K; Miyamoto H; Muguruma N; Furuhata T; Takemasa I; Kato J; Takayama T
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1133-1139. PubMed ID: 29038850
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
Shitara K; Ura T; Matsuo K; Takahari D; Yokota T; Yuki S; Yoshida M; Utsunomiya S; Sato Y; Yamaura H; Kato M; Inaba Y; Tajika M; Kawai H; Yamazaki K; Komatsu Y; Muro K
Eur J Cancer; 2011 Dec; 47(18):2673-80. PubMed ID: 21652203
[TBL] [Abstract][Full Text] [Related]
27. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
[TBL] [Abstract][Full Text] [Related]
28. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Iwamoto S; Hazama S; Kato T; Miyake Y; Fukunaga M; Matsuda C; Bando H; Sakamoto J; Oba K; Mishima H
Anticancer Res; 2014 Apr; 34(4):1967-73. PubMed ID: 24692733
[TBL] [Abstract][Full Text] [Related]
29. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
Tanioka H; Shimada K; Tsuji A; Kochi M; Kim HM; Takahashi T; Denda T; Takagane A; Watanabe T; Kotaka M; Nakamura M; Sunakawa YU; Takeuchi M; Ichikawa W; Fujii M
Anticancer Res; 2022 May; 42(5):2675-2681. PubMed ID: 35489740
[TBL] [Abstract][Full Text] [Related]
30. Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Takaoka T; Kimura T; Shimoyama R; Kawamoto S; Sakamoto K; Goda F; Miyamoto H; Negoro Y; Tsuji A; Yoshizaki K; Goji T; Kitamura S; Yano H; Okamoto K; Kimura M; Okahisa T; Muguruma N; Niitsu Y; Takayama T
Cancer Chemother Pharmacol; 2016 Aug; 78(2):397-403. PubMed ID: 27342247
[TBL] [Abstract][Full Text] [Related]
31. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
32. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frödin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Mauro DJ; Watkins DJ
J Natl Cancer Inst; 2015 Dec; 107(12):djv258. PubMed ID: 26405092
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
Nakamura M; Aoyama T; Ishibashi K; Tsuji A; Takinishi Y; Shindo Y; Sakamoto J; Oba K; Mishima H
Cancer Chemother Pharmacol; 2017 Jan; 79(1):29-36. PubMed ID: 27878354
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study.
Lim R; Sun Y; Im SA; Hsieh RK; Yau TK; Bonaventura A; Cheirsilpa A; Esser R; Mueser M; Advani S
World J Gastroenterol; 2011 Apr; 17(14):1879-88. PubMed ID: 21528063
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Garrett CR; Bekaii-Saab TS; Ryan T; Fisher GA; Clive S; Kavan P; Shacham-Shmueli E; Buchbinder A; Goldberg RM
Cancer; 2013 Dec; 119(24):4223-30. PubMed ID: 24105075
[TBL] [Abstract][Full Text] [Related]
36. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
Buzaid AC; Mathias Cde C; Perazzo F; Simon SD; Fein L; Hidalgo J; Murad AM; Esser R; Senger S; Lerzo G
Clin Colorectal Cancer; 2010 Dec; 9(5):282-9. PubMed ID: 21208842
[TBL] [Abstract][Full Text] [Related]
38. A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401).
Samura H; Oki E; Okumura H; Yoshida T; Kai S; Kobayashi K; Kinjo T; Mori S; Tohyama T; Ohgaki K; Kawanaka H; Makiyama A; Ureshino N; Kotaka M; Shimose T; Ando K; Saeki H; Baba H; Maehara Y; Mori M
Cancer Chemother Pharmacol; 2020 Aug; 86(2):285-294. PubMed ID: 32734398
[TBL] [Abstract][Full Text] [Related]
39. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
Asai H; Shinozaki E; Nozaki A; Watanabe T; Suenaga M; Matuzaka S; Chin K; Mizunuma N; Yasukawa M; Hatake K
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1285-91. PubMed ID: 21829065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
